TIMI risk score underestimates prognosis in unstable angina/non-ST segment elevation myocardial infarction

Acute Cardiac Care

Volumn 10, Issue 1, 2008, Pages 26-29

  Vorlat, Anne ^a   Claeys, Marc J ^a   De Raedt, Herbert ^b   Gevaert, Sofie ^c   Vandekerckhove, Yves ^d   Dubois, Philippe ^e   De Meester, Antoine ^f   Vrints, Christiaan ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Service de Cardiologie   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d General Hospital St Jan   (Belgium)

^e Centre Hospitalier Universitaire de Charleroi   (Belgium)

^f Department of Cardiology ^*

Author keywords

Biomarkers; Mortality; Myocardial infarction; TIMI risk score

Indexed keywords

TROPONIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; VALIDATION PROCESS;

AGED; ANGINA, UNSTABLE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; RECURRENCE; RISK ASSESSMENT;

EID: 45849101635     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701537902     Document Type: Article

References (16)

1. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-42.
2. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, et al. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004;25:1139-45.
3. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223-9.
4. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-601.
5. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events study group. N Engl J Med. 1997;337:447-52.
6. Sabatine MS, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;41(Suppl S):89S-95S.
7. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-87.
8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. N Engl J Med. 1998;338:1488-97.
9. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502-13.
10. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102:1193-209.
11. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It's time for a change to a troponin standard. Circulation. 2000;102:1216-20.
12. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001;103:1832-7.
13. Yan AT, Yan RT, Tan M, Chow CM, Fitchett D, Stanton E, et al. Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. Eur Heart J. 2004;25:2006-12.
14. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-604.
15. de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865-72.
16. Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. Eur Heart J. 2006;27:1706-11.